Analysis of biologic surrogate markers from a children's oncology group phase I trial of gefitinib in pediatric patients with solid tumors

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 352-357

  Jimeno, Antonio ^a   Daw, Najat C ^b,c   Amador, Maria L ^a   Cusatis, George ^a   Kulesza, Peter ^d   Krailo, Mark ^e   Ingle, Ashish M ^f   Blaney, Susan M ^g   Adamson, Peter ^h   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

EGFR; Gefitinib; MMP 2; MMP 9; VEGF

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELATINASE A; GELATINASE B; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFECT; EGFR GENE; EWING SARCOMA; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547788184     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20753     Document Type: Article

References (35)

1. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-643.
2. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
5. Giordano A, Rustum YM, Wenner CE. Cell cycle: Molecular targets for diagnosis and therapy: Tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem 1998;70:1-7.
6. de Jong JS, van Diest PJ, van der Valk P, et al. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998;184:53-57.
7. Wells A. Tumor invasion: Role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101.
8. Gibson EM, Henson ES, Haney N, et al. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 2002;62:488-496.
9. Meyers MB, Shen WP, Spengler BA, et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988;38:87-97.
10. Zhang L, Jope RS. Muscarinic M3 and epidermal growth factor receptors activate mutually inhibitory signaling cascades in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 1999;255:774-777.
11. De Giovanni C, Landuzzi L, Frabetti F, et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res 1996;56:3898-3901.
12. Ricci C, Polito L, Nanni P, et al. HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J Immunother 2002;25:314-323.
13. Layfield LJ, Thompson JK, Dodge RK, et al. Prognostic indicators for neuroblastoma: Stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr - a survival study. J Surg Oncol 1995;59:21-27.
14. Ghanem MA, Van Der Kwast TH, Den Hollander JC, et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 2001;92:3120-3129.
15. Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-2053.
16. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-1792.
17. Nguyen DM, Desai S, Chen A, et al. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg 2000;70:1853-1860.
18. Oc P, Modjtahedi H, Rhys-Evans P, et al. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 2000;60:1121-1128.
19. Liu Z, Klominek J. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. Neoplasia 2004;6:705-712.
20. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-2355.
21. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-1914.
22. Anderson NG, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001;94:774-782.
23. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-1465.
24. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
25. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
26. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
27. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004;64:9101-9104.
28. Gregorc V, Ceresoli GL, Floriani I, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:6006-6012.
29. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2005;23:6172-6180.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
31. Jimeno A, Rubio-Viqueira B, Amador ML, et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005;65:3003-3010.
32. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356-2362.
33. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002;3:125-135; discussion 136-127.
34. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
35. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003;290:2149-2158.